Kornitzer Capital Management Inc. KS held its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 60,300 shares of the company’s stock at the end of the second quarter. Kornitzer Capital Management Inc. KS owned 0.26% of Oxford Immunotec Global PLC worth $1,014,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quantitative Systematic Strategies LLC purchased a new position in shares of Oxford Immunotec Global PLC during the first quarter valued at $156,000. Parkwood LLC purchased a new position in shares of Oxford Immunotec Global PLC during the first quarter valued at $176,000. American International Group Inc. boosted its position in shares of Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after buying an additional 904 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Oxford Immunotec Global PLC by 1.9% in the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after buying an additional 254 shares during the last quarter. Finally, TFS Capital LLC boosted its position in shares of Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock valued at $219,000 after buying an additional 2,337 shares during the last quarter. 87.03% of the stock is currently owned by hedge funds and other institutional investors.

Oxford Immunotec Global PLC (OXFD) opened at 18.02 on Tuesday. The firm’s market cap is $415.83 million. The firm has a 50-day moving average of $16.18 and a 200-day moving average of $14.93. Oxford Immunotec Global PLC has a 52-week low of $8.88 and a 52-week high of $19.51.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting analysts’ consensus estimates of ($0.32). The firm had revenue of $26.10 million during the quarter, compared to analysts’ expectations of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The firm’s quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) EPS. Equities analysts anticipate that Oxford Immunotec Global PLC will post ($1.07) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Oxford Immunotec Global PLC (NASDAQ:OXFD) Stake Maintained by Kornitzer Capital Management Inc. KS” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/08/oxford-immunotec-global-plc-nasdaqoxfd-stake-maintained-by-kornitzer-capital-management-inc-ks.html.

Several research analysts have recently weighed in on the stock. Piper Jaffray Companies reissued a “buy” rating and set a $26.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine raised shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BTIG Research reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Thursday, May 4th. Finally, Cowen and Company reissued a “buy” rating and set a $22.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $21.00.

In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 32,832 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $16.58, for a total value of $544,354.56. Following the sale, the chief executive officer now directly owns 478,106 shares of the company’s stock, valued at approximately $7,926,997.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Elizabeth M. Keiley sold 4,085 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $15.01, for a total value of $61,315.85. Following the completion of the sale, the vice president now directly owns 25,393 shares in the company, valued at $381,148.93. The disclosure for this sale can be found here. In the last quarter, insiders have sold 107,085 shares of company stock valued at $1,710,328. 7.58% of the stock is currently owned by company insiders.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.